Neo-adjuvant ipilimumab and nivolumab in high risk resectable bladder urothelial cancer (NABUCCO)

N. van Dijk; C. U. Blank; P. Kvistborg; T. N. Schumacher; E. Hooijberg; K. Sikorska; B. V. Rhijn; M. S. van der Heijden

doi:https://doi.org/10.1093/annonc/mdy283.135

Neo-adjuvant ipilimumab and nivolumab in high risk resectable bladder urothelial cancer (NABUCCO)

N. van Dijk, C. U. Blank, P. Kvistborg, T. N. Schumacher, E. Hooijberg, K. Sikorska, B. V. Rhijn, M. S. van der Heijden

Amsterdam UMC

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	viii329
Journal	Annals of Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy283.135
Publication status	Published - 1 Oct 2018

Access to Document

https://doi.org/10.1093/annonc/mdy283.135

Cite this

@article{ad212a6d38134a25ac45b0029d7df5bc,

title = "Neo-adjuvant ipilimumab and nivolumab in high risk resectable bladder urothelial cancer (NABUCCO)",

author = "{van Dijk}, N. and Blank, {C. U.} and P. Kvistborg and Schumacher, {T. N.} and E. Hooijberg and K. Sikorska and Rhijn, {B. V.} and {van der Heijden}, {M. S.}",

year = "2018",

month = oct,

day = "1",

doi = "https://doi.org/10.1093/annonc/mdy283.135",

language = "English",

volume = "29",

pages = "viii329",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Neo-adjuvant ipilimumab and nivolumab in high risk resectable bladder urothelial cancer (NABUCCO)

AU - van Dijk, N.

AU - Blank, C. U.

AU - Kvistborg, P.

AU - Schumacher, T. N.

AU - Hooijberg, E.

AU - Sikorska, K.

AU - Rhijn, B. V.

AU - van der Heijden, M. S.

PY - 2018/10/1

Y1 - 2018/10/1

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85081532547&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/32136773

U2 - https://doi.org/10.1093/annonc/mdy283.135

DO - https://doi.org/10.1093/annonc/mdy283.135

M3 - Article

C2 - 32136773

SN - 0923-7534

VL - 29

SP - viii329

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Neo-adjuvant ipilimumab and nivolumab in high risk resectable bladder urothelial cancer (NABUCCO)

Access to Document

Other files and links

Cite this